Cardiac Resynchronization Therapy in Pulmonary Hypertension (CRT in PH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03077139 |
Recruitment Status :
Completed
First Posted : March 10, 2017
Last Update Posted : September 20, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pulmonary Hypertension | Device: Cardiac Resynchronization Therapy (CRT) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Cardiac Resynchronization Therapy in Pulmonary Hypertension |
Actual Study Start Date : | November 29, 2012 |
Actual Primary Completion Date : | March 23, 2017 |
Actual Study Completion Date : | March 23, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Arms
Pacing wires used to stimulate ventricles in a synchronous matter
|
Device: Cardiac Resynchronization Therapy (CRT)
A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern. |
- 15% increase in cardiac output at the optimal VV interval over baseline cardiac output [ Time Frame: the procedure ]Primary Outcome

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pulmonary hypertension, defined as pulmonary artery systolic pressure greater than 40 mm Hg by transthoracic echocardiogram or right heart catheterization
- LVEF ≥ 50%
- Baseline 6MWT distant <400 meters
- Baseline NYHA Functional class ≥ III
Exclusion Criteria:
- LVEF < 50%
- 6MWT duration > 400 meters
- NYHA Functional class < III
- Left bundle branch block
- Non-sinus rhythm
- Severe aortic stenosis (Aortic valve area < 1 cm2)
- Severe mitral regurgitation
- Acute cardiac failure
- Dependency on intravenous inotropies
- Severe obstructive pulmonary disease
- Hypertrophic obstructive cardiomyopathy
- Amyloidosis
- Dependence on pacing

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03077139
United States, Louisiana | |
Ochsner Medical Center | |
New Orleans, Louisiana, United States, 70121 |
Principal Investigator: | Daniel Morin, MD | Cardiac Electrophysiologist |
Responsible Party: | Dr. Daniel P Morin, MD MPH FHRS, Cardiac Electrophysiologist, Ochsner Health System |
ClinicalTrials.gov Identifier: | NCT03077139 History of Changes |
Other Study ID Numbers: |
CRT in PH |
First Posted: | March 10, 2017 Key Record Dates |
Last Update Posted: | September 20, 2017 |
Last Verified: | September 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Hypertension, Pulmonary Hypertension Vascular Diseases |
Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |